stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Current ratio
Beam Therapeutics Inc.'s current ratio at the end of the quarter to 30 September 2026 was 13.0×, down 0.1× from fiscal 2025 (13.1×). Over the past ten years it has ranged from 0.3× (fiscal 2017) to 13.1× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 13.1× | 171.36% |
| FY2024 | 4.8× | (18.13%) |
| FY2023 | 5.9× | 20.53% |
| FY2022 | 4.9× | (18.05%) |
| FY2021 | 6.0× | 97.97% |
| FY2020 | 3.0× | (7.15%) |
| FY2019 | 3.2× | (44.01%) |
| FY2018 | 5.8× | 1,928.32% |
| FY2017 | 0.3× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 13.0× | (10.75%) |
| Jun 2026 | 14.6× | (14.24%) |
| Mar 2026 | 17.0× | 29.82% |
| Dec 2025 | 13.1× | 117.50% |
| 25 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| MBX MBX Biosciences, Inc. compare | 18.1× |
| VRDN Viridian Therapeutics, Inc. compare | 14.5× |
| BEAM Beam Therapeutics Inc. | 13.0× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 11.8× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.0× |
| XNCR Xencor, Inc. compare | 6.4× |
| RCUS Arcus Biosciences, Inc. compare | 3.3× |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 2.0× |
| TLX Telix Pharmaceuticals Limited compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement